免疫检查点抑制剂治疗恶性肿瘤的群体药代动力学研究进展  

Research progress in population pharmacokinetics of immune checkpoint inhibitors in the treatment of malignant tumors

作　　者：高佩玉 喜鹏 董治银 宋霞[2] GAO Peiyu;XI Peng;DONG Zhiyin;SONG Xia(Pharmacy Department,the Second People’s Hospital of Dingxi City,Gansu,Dingxi 743000,China;Pharmacy Department,Lanzhou University Second Hospital,Gansu,Lanzhou 730030,China)

机构地区：[1]甘肃省定西市第二人民医院药剂科,甘肃定西743000 [2]兰州大学第二医院药剂科,甘肃兰州730030

出　　处：《中国医药科学》2024年第1期47-51,107,共6页China Medicine And Pharmacy

基　　金：兰州大学第二医院“萃英学子科研培育计划”项目(CYXZ2023-26)。

摘　　要：以免疫检查点抑制剂(ICIs)为代表的靶向单克隆抗体类抗肿瘤药物可阻断ICIs分子与其配体的结合,从而通过增强T细胞免疫活性促进肿瘤细胞清除,这在改善几种预后不良的恶性肿瘤总生存率方面显示出显著的临床效果。群体药代动力学(PPK)可表征药物在特定人群中的药代动力学(PK)特征,为个体化用药提供参考。目前关于ICIs的PPK研究报道日益增多。本文综述常见抗肿瘤ICIs类药物的PPK研究进展,列举各类药物的PPK模型结构参数及其协变量,并总结药物是否需要根据相关影响因素进行给药方案的调整,以期为临床合理使用ICIs药物及其药动-药效学(PK-PD)研究提供参考。Targeted monoclonal antibody antineoplastic drugs represented by immune checkpoint inhibitors(ICIs)can block the binding of ICIs molecules to their ligands,thereby promoting tumor cell clearance by enhancing T cell immune activity,and demonstrating significant clinical effects in improving the overall survival rate of several malignant tumors with poor prognoses.Population pharmacokinetics(PPK)can describe the pharmacokinetic(PK)characteristics of drugs in specific populations,providing a reference for individualized medication.Currently,there are increasing reports on the PPK of ICIs.This paper reviews the research progress of PPK on common antineoplastic drugs of ICIs,lists the structural parameters and covariates of PPK models for various drugs,and summarizes whether the drug regimen needs to be adjusted according to relevant influencing factors,in order to provide a reference for the rational use of ICIs in clinical practice and their pharmacokineticpharmacodynamic(PK-PD)studies.

关 键 词：免疫检查点抑制剂 靶向抗肿瘤药物 个体化用药 群体药动学 

分 类 号：R730.5[医药卫生—肿瘤]